Everest marks a new chapter in market confidence as Hong Kong Exchange grants removal of its “B” designation.

NEFECON®, as the only approved IgAN therapy in China, generated RMB353.4 million in revenue for the year, representing a year-over-year increase of 1,581%. NEFECON® was also included in China’s ...

In this webinar, Benoit Derrien will discuss new strategies using enzymatically synthesized DNA for gene construction.

Imagine a world without the internet, or GPS, MRNA vaccines or the touchscreen on your iPhone. The science and technology that have become integral to our daily lives ...